Drugs / CYT013-IL1bQb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00924105 | Jun 2009 → Nov 2011 | type 2 diabetes mellitus | Cytos Biotechnology AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYT013-IL1bQb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00924105 ↗ |
| Action | Inhibit | “suggesting reduction of IL-1β activity as new treatment strategy” PMID 26686385 ↗ Dec 2015 |
| Route | Subcutaneous | “s.c. injection” NCT00924105 ↗ |